Phase 1 Study of HLA-A*2402 Restricted Antiangiogenic Peptide Vaccine Therapy Using Epitope Peptide Derived Feom VEGFR1 and VEGFR2 in Treating Patients With Unresectable, Recurrent, or Metastatic Hepatocellular Carcinoma
It has been required to develop new treatment modalities for patients with advanced
heptatocellular carcinoma. Immunotherapy is one of the encouraging modalities for patients.
We have to assess its toxicities, clinical response and immune responsiveness.
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Toxicities as assessed by NCI-CACAE ver3
Mitsukazu Gotoh, PhD & MD
Fukushima Medical University, Department of Regeneration Surgery
Japan: Institutional Review Board